A Multicenter, Open-Label, Phase 2 Study of NGX-4010 for the Treatment of Neuropathic Pain in Patients with Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN), NeurogesX. Grant uri icon